Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma (Q44833504)

6 December 2017

title

Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma (English)

1 reference

6 December 2017

0 references

1

1 reference

6 December 2017

Raffaella Tortora

2

1 reference

6 December 2017

Massimo De Luca

3

1 reference

6 December 2017

Alfonso Galeota Lanza

4

1 reference

6 December 2017

Filippo Lampasi

5

1 reference

6 December 2017

Maria Teresa Tartaglione

6

1 reference

6 December 2017

Francesco Paolo Picciotto

7

1 reference

6 December 2017

Michele Imparato

8

1 reference

6 December 2017

Silvana Mattera

9

1 reference

6 December 2017

Gabriella Cordone

10

1 reference

6 December 2017

Antonio Ascione

11

1 reference

6 December 2017

publication date

10 January 2013

1 reference

6 December 2017

1 reference

6 December 2017

volume

30

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

446

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-012-0446-y

6 December 2017

exact match

0 references

cites work

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Geriatric oncology: challenges for the new century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

The presentation, treatment and outcome of renal cell carcinoma in old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Medical care costs and survival associated with hepatocellular carcinoma among the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0446-Y

Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study.

21 January 2018

1 reference

12 December 2020

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

1 reference

12 December 2020

Epidemiology of hepatocellular carcinoma in USA

1 reference

12 December 2020

Management of cancer in the older person: a practical approach

1 reference

12 December 2020

Altered angiogenesis underlying age-dependent changes in tumor growth

1 reference

12 December 2020

Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance

1 reference

12 December 2020

Efficacy of anti-angiogenic treatment of tumors in old versus young mice

1 reference

12 December 2020

10.1007/S12032-012-0446-Y

Identifiers

DOI

1 reference

6 December 2017

1 reference